Latest Headlines

Latest Headlines

GSK grabs FDA nod for combo meningitis vax

U.S. regulators have stamped an approval on GlaxoSmithKline's combination meningitis vaccine, which is supposed to provide wide coverage against the life-threatening disease for young infants. The FDA's approval of the product, called Menhibrix, could give the London-based drugmaker an edge in the market for meningitis vaccines.

Pfizer targets PhIII with pioneering meningitis B vax

Pharma giant Pfizer is making progress in the Phase II trial of a vaccine for meningitis serogroup B, for which there are no such preventive treatments available. This week the New York-based drugmaker's trial got some ink from media near some of the study sites in the Midwest.

Pneumococcal vax cuts deaths, but cases tripled

While vaccines against Streptococcus pneumoniae have cut the number of deaths from this bug that can cause pneumonia and meningitis, the number of cases has tripled in the past 50 years.

UPDATED: Teen meningitis B vax successful in Phase II

A team from Australia has shown positive immune responses in a Phase II trial of Pfizer's meningitis B vaccine in teenagers.

Nimenrix meningitis vaccine edges closer to the market for GSK

The European Medicines Agency has recommended approval for GlaxoSmithKline's ($GSK) conjugate vaccine against meningococcal disease in adults and children from the age of 12 months. The active...

Novartis' Bexsero successfully protects vast majority of infants

A vaccine against meningococcal B disease, a devastating bacterial infection that is hard to diagnose and can kill in 24 hours, has come a step closer with infant Phase IIb data for Novartis' ($NVS)

Novartis' meningitis B vaccine aces study en route to market

The remaining type of meningitis for which no vaccine exists has finally met its match. In a study backed by Novartis ($NVS), researchers found the Swiss drug giant's experimental vaccine, dubbed...

Cheap meningitis vax beats out GSK's version

Serum Institute of India's vaccine for meningitis beat out pricier alternatives from other vaccine makers, including GlaxoSmithKline. That's according to a study published in the New England Journal

Novartis vax against MenB shows benefits in infant study

Novartis appears to have made more progress in the battle against meningitis B. The Swiss drug giant says that its experimental vaccine Bexsero (a.k.a. 4CMenB) could protect against about 80 percent

GAVI Alliance pours $100M into meningitis vaccine

The GAVI Alliance has committed $100 million to support a meningitis A vaccine called MenAfriVac developed by Seattle-based PATH. The vaccine, which was developed with the help of a $70 million